Mulas Olga

List of Publications by Year
in descending order

32 papers	422 citations	933447 10 h-index	752698 20 g-index
32 all docs	32 docs citations	32 times ranked	595 citing authors

#	Article	IF	Citations
1	Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis. Annals of Hematology, 2022, 101, 929-931.	1.8	19
2	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Frontiers in Oncology, 2022, 12, 835563.	2.8	6
3	Conditioning Regimens in Patients with Î²-Thalassemia Who Underwent Hematopoietic Stem Cell Transplantation: A Scoping Review. Journal of Clinical Medicine, 2022, 11, 907.	2.4	9
4	Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. Acta Haematologica, 2021, 144, 322-326.	1.4	0
5	The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. Journal of Public Health Research, 2021, 10, .	1.2	2
6	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	2.8	6
7	Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 674748.	3.5	7
8	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	1.8	14
9	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. Blood, 2021, 138, 1487-1487.	1.4	0
10	Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?. Blood, 2021, 138, 2573-2573.	1.4	2
11	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Blood, 2021, 138, 1479-1479.	1.4	1
12	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. International Journal of Cardiology, 2020, 301, 163-166.	1.7	21
13	Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers, 2020, 12, 3497.	3.7	10
14	Favorable outcome of chronic myeloid leukemia coâ€expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 2020, 38, 607-610.	1.7	1
15	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	1.8	9
16	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	6.2	6
17	Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting. International Journal of Hematology, 2020, 111, 614-618.	1.6	6
18	Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. Journal of Clinical Medicine, 2020, 9, 1180.	2.4	9

#	Article	IF	Citations
19	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) Tj ETQq1 1 0.784314 rgBT /Overloc		
20	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
21	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. Blood, 2020, 136, 8-9.	1.4	0
22	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Annals of Hematology, 2019, 98, 1885-1890.	1.8	10
23	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. International Journal of Cardiology, 2019, 288, 124-127.	1.7	19
24	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the realâ€life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematological Oncology, 2019, 37, 296-302.	1.7	53
25	Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience. Blood, 2019, 134, 4186-4186.	1.4	0
26	Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors. Blood, 2019, 134, 4144-4144.	1.4	2
27	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with secondâ€generation tyrosine kinase inhibitors in the realâ€life practice: Identification of risk factors and the role of prophylaxis. American Journal of Hematology, 2018, 93, E159-E161.	4.1	26
28	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Frontiers in Oncology, 2018, 8, 194.	2.8	84
29	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. Blood, 2018, 132, 3006-3006.	1.4	1
30	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. Leukemia Research, 2017, 61, 1-5.	0.8	12
31	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental Hematology, 2015, 43, 1015-1018.e1.	0.4	51
32	Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Experimental Hematology, 2013, 41, 424-431.	0.4	32